梯度扩散法检测产金属β-内酰胺酶肠杆菌对氨曲南-阿维巴坦敏感性的评估
该研究评估了氨曲南/阿维巴坦梯度扩散条对103株产金属β-内酰胺酶(MBL)肠杆菌临床分离株及31株CDC AR Bank分离株的药敏检测性能。与肉汤微量稀释法(BMD)相比,临床分离株的基本一致率为93.2%,分类一致率为97.1%(采用CLSI氨曲南折点),无重大或极重大错误,精密度为100%。结果表明梯度扩散法是临床实验室测定氨曲南-阿维巴坦MIC的可行选择。
要点
- 梯度扩散条与BMD的基本一致率达93.2%,分类一致率达97.1%。
- 无重大或极重大错误,仅出现3个次要错误,精密度为100%。
- 梯度扩散法可作为临床实验室检测氨曲南-阿维巴坦MIC的可行方法。
核心结论
- 氨曲南-阿维巴坦梯度扩散法在产MBL肠杆菌中与BMD具有良好一致性,可作为临床实验室的可行检测选项。
研究设计与样本
- 研究评估了氨曲南/阿维巴坦梯度扩散条对103株产MBL肠杆菌临床分离株及31株CDC AR Bank分离株的检测性能,所有临床分离株均携带blaNDM基因。
主要发现
- 临床分离株梯度扩散条MIC与BMD的基本一致率为93.2%。
- 采用CLSI氨曲南折点时,临床分离株的分类一致率为97.1%。
- 未观察到重大或极重大错误,出现3个次要错误。
- 氨曲南-阿维巴坦梯度扩散法的精密度为100%。
关键数值与推荐
- 基本一致率93.2%(临床分离株,梯度扩散条 vs BMD)。
- 分类一致率97.1%(临床分离株,采用CLSI氨曲南折点)。
- 无重大或极重大错误,3个次要错误,精密度100%。
临床怎么用
- 临床实验室可采用梯度扩散法测定产MBL肠杆菌对氨曲南-阿维巴坦的MIC,以支持联合治疗方案的药敏报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of metallo-β-lactamase (MBL)-producing Enterobacterales presents unique clinical treatment challenges. Recently developed β-lactam/ β-lactamase inhibitor combination agents, while effective against other carbapenemase-producing organisms, are notably ineffective against MBL producers. While MBLs do not hydrolyze monobactams (aztreonam), many MBL-producing organisms are resistant to aztreonam through alternate mechanisms, leaving cefiderocol as the sole monotherapy treatment option recommended for MBL producers. Recent guidelines for the treatment of MBL-harboring organisms have added combination therapy with aztreonam and ceftazidime-avibactam, using ceftazidime-avibactam as a source of the β-lactamase inhibitor avibactam. Current laboratory testing options for the combination of aztreonam-avibactam are limited to broth microdilution (BMD) and broth disk elution (BDE) methods, which are not practical in most clinical laboratories. In this study, we evaluated the performance of aztreonam/avibactam gradient strips on 103 MBL-producing Enterobacterales patient isolates as well as an additional 31 isolates from the CDC AR Bank. All MBL Enterobacterales patient isolates included in this study harbored a New Delhi metallo-β-lactamase (blaNDM) gene. Essential agreement of gradient strip minimal inhibitory concentrations (MICs) for patient isolates compared to BMD was 93.2%. While there are no established breakpoints for aztreonam-avibactam, category agreement (CA) for patient isolates was 97.1% when using the CLSI aztreonam breakpoints. There were no major or very major errors observed. There were three minor errors. Precision for aztreonam-avibactam gradient strip diffusion was 100%. These data demonstrate that the use of gradient strip diffusion for aztreonam-avibactam MIC determination in MBL-producing Enterobacterales is a viable option for clinical laboratories.
引用
- Lemon JK, Jankowsi-Romano C, Duong S, et al. Evaluation of gradient strip diffusion for susceptibility testing of aztreonam-avibactam in metallo-β-lactamase-producing Enterobacterales. J Clin Microbiol. 2024. PMID: 39345139. doi:10.1128/jcm.00649-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。